All In Biotech

NDA 215500 · Uswm

Iwilfin

Eflornithine Hydrochloride · Oral

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Dec 13, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

53

11 Phase 3, 11 recruiting

FAERS reports

42

31 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2026.

IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. IWILFIN is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. ( 1 )

Mechanism: Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of MYCN . Polyamines are involved in differentiation and proliferation of mammalian cells and are important for neoplastic transformation. Inhibition of polyamine synthesis by eflornithine restored the balance of the LIN28/Let-7 metabolic pathway, which is involved in regulation of cancer stem cells and glycolytic metabolism, by decreasing expression of the oncogenic drivers MYCN and LIN28B in MYCN -amplified...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 13, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLetterLabelReview
1 products under this application
  • IWILFIN · EFLORNITHINE HYDROCHLORIDE EQ 192MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eflornithine" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death7
  • deafness6
  • alopecia5
  • condition aggravated5
  • disease progression4
  • neuroblastoma4
  • disease recurrence2
  • dry mouth2
  • eyelash changes2
  • joint dislocation2
  • motor developmental delay2
  • off label use2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20071
20131
20151
20161
20181
20201
20211
20221
20233
202418
20256
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Uswm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.